Division of Health Care Finance
Landon State Office Building
900 SW Jackson, Suite 900 N
Topeka, KS 66612-1220

Kansas Department of Health and Environment

Phone: 785-296-3981
Fax: 785-296-4813
www.kdheks.gov

Janet Stanek, Secretary

Laura Kelly, Governor

Drug Utilization Review Board Meeting
Agenda, Open Session October 19, 2022
10:00 a.m. – 2:00 p.m.

Meeting Location*

*Due to COVID-19, this meeting will be held virtually. Please use the information below to join the meeting:
Computer Audio Enabled Zoom Meeting: https://us02web.zoom.us/j/86960889427
Required Passcode: 799854 **Audio Dial in:** (877) 853-5257 US Toll-free**, Meeting ID:** 869 6088 9427
Members of the general public are required to complete a conflict-of-interest form if they intend to provide public comments to the Board. To assist the operator in coordinating public comment, completed forms are due 1 week prior to the meeting (October 12, 2022). Please email the completed form to Annette.Grant@ks.gov.

Board Members

Moneeshindra Mittal, MD (Chair)
James Backes, PharmD
Gregory Burger, PharmD, CPPS, FASHP, EMT
Daryl J. Callahan, D.O., M.S.S.
Cori Durall, PharmD
Jennifer Clair, MD
Kristen Powell, PharmD
Michele Reisinger, DNP, APRN, FNP-BC
Arthur Snow, MD

KDHE-DHCF Staff

Annette Grant, RPh
Victor Nguyen, PharmD
Sridevi Donepudi, MD
Carol Arace, Training Coordinator

Gainwell Technologies/KEPRO Staff

Karen Kluczykowski, RPh
Kathy Kaesewurm, RN, BSN
Harry Vu, PharmD
Debra Illions-Clark, LPN
Christina Faulkner, PharmD, BCPS
Jordan Brazeal, PharmD

MCO Staff

Mark DeMary, PharmD, **Aetna Better Health of Kansas**
Angie Yoo, PharmD, **Sunflower State Health Plan**
Sunny Bounyalath, PharmD, **UnitedHealthcare Community Plan**

I. CALL TO ORDER

A. Announcements

This meeting will be operator-assisted. An opportunity for public comment was given at the top of the agenda.

II. OLD BUSINESS

A. Review and Approval of July 20, 2022 Meeting Minutes

III. NEW BUSINESS

A. Executive Sign-off – Approval of Process

This process is intended to streamline the Board's approval procedures for simple and standard updates to existing PA criteria. These changes may include additions of new formulations/strengths/dosing regimens/biosimilars where indications are the same.

i. Review of Process
ii. *Public Comment
iii. Board Discussion

B. Executive Sign-off Agenda Items – Revised Prior Authorization (PA) Criteria

1. **Ankylosing Spondylitis Agents**
   This revision includes the addition of Rinvoq® to the list of agents requiring prior authorization and updates a blanket statement regarding other FDA-approved indications.

2. **Enzyme Replacement Therapy**
   This revision includes the addition of Xenpozyme™ to the list of agents requiring prior authorization and updates a blanket statement regarding other FDA-approved indications.

3. **Minimum Requirements Prior Authorization (MRPA)**
   This revision includes updates to indicated age groups and dosing for Orkambi® and Diacomit® and updates a blanket statement regarding other FDA-approved indications.

4. **Plaque Psoriasis Agents**
   This revision includes the addition of Sotyktu™ to the list of agents requiring prior authorization, updates the indicated age groups for Stelara® and Cosentyx®, and updates a blanket statement regarding other FDA-approved indications.

5. **Spinal Muscular Atrophy (SMA) Agents**
   This revision includes updates to indicated age groups and dosing for Evrysdi® and updates a blanket statement regarding other FDA-approved indications.

i. Review of agenda items for Executive Sign-off
ii. Board Discussion

C. Revised Prior Authorization (PA) Criteria

1. **Growth Hormone Agents** (previously Somatropin Products)
   This revision updates criteria for initiation of growth hormone in pediatric populations.

i. Revised PA Criteria
ii. *Public Comment
iii. Board Discussion

2. **Weight Loss Agents**
   This revision includes an update to indicated age groups for Qsymia® and revisions to pediatric criteria.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

3. **Synagis® (palivizumab)**
   This revision updates the criteria to allow for providers to submit data for evaluation for when local trends do not align with the CDC National Respiratory and Enteric Virus Surveillance System.
   i. Revised PA Criteria
   ii. *Public Comment
   iii. Board Discussion

D. New Prior Authorization (PA) Criteria

1. **Beta-Thalassemia Agents**
   Zynteglo® (betibeglogene autotemcel) is a hematopoietic stem cell-based gene therapy recently approved for the treatment of transfusion dependent β-thalassemia. The prior authorization criteria are being proposed to ensure appropriate use based upon the FDA-approved labeling information and clinical guidelines.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

2. **Thyroid Eye Disease Agents**
   Tepezza® (teprotumumab) is an insulin-like growth factor-1 receptor inhibitor (IGF-1R) approved for the treatment of thyroid eye disease, also known as Graves' Orbitopathy. The prior authorization criteria are being proposed to ensure appropriate use based upon FDA-approved labeling information and clinical guidelines.
   i. Prior Authorization Criteria
   ii. *Public Comment
   iii. Board Discussion

E. Tentative Agenda Items (MHMAC Meeting Agenda Items)

1. **MHMAC Meeting (October 18, 2022)**

   a. Antidepressant Medications – Safe Use for All Ages
      -Addition of Auvelity™.
      i. Prior Authorization Criteria
      ii. *Public Comment
      iii. Board Discussion

F. Miscellaneous Items

1. **Fee-for-Service Annual Program Assessment**
   The annual program assessment for the Medicaid fee-for-service population will be presented to show drug trends over the past state fiscal year.
   i. Presentation
   ii. Board Discussion

2. **Managed Care Annual Program Assessment**
   Aetna Better Health of Kansas, Sunflower State Health Plan, and UnitedHealthcare Community Plan will present their annual DUR Program activity report.
   i. Aetna Individual Report – Mark DeMary, PharmD
   ii. Sunflower Individual Report – Angie Yoo, PharmD
   iii. UnitedHealthcare Individual Report – Sunny Bounyalath, PharmD
   iv. *Public Comment
   v. Board Discussion

IV. ADJOURN

The next DUR Board meeting is scheduled for January 18, 2023.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board's discretion. Informal comments will be accepted from members of the audience at various points in the agenda.

****THIS AGENDA IS SUBJECT TO CHANGE****